Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy

NCT00630747 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT00630747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00630747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Lead sponsor
Shire
Phase
Phase 2/3
Overall status
Completed
Start date
September 13, 2004
Completion date
January 31, 2008
Enrollment
94 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

hunter syndrome, mucopolysaccharidosis ii (mps ii)